Ripcord Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 5.00 M
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.88 Cr
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets 13.88%
About Ripcord Pharmaceuticals
Ripcord Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 November 2017 (Seven years and two months 27 days old ). Its registered office is in Kolhapur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.88 Cr.
Komal Madhu, Indu Madhu, Bhavin Madhu, and One other member serve as directors at the Company.
Company Details
-
Location
Kolhapur, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999PN2017PTC173517
-
Company No.
173517
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Nov 2017
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Ripcord Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhavin Madhu
|
Managing Director | 21-Nov-2017 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Mihir Madhu
|
Director | 21-Nov-2017 | Current |
|
Komal Madhu
|
Director | 21-Nov-2017 | Current |
|
Indu Madhu
|
Director | 21-Nov-2017 | Current |
Financial Performance of Ripcord Pharmaceuticals.
Ripcord Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ripcord Pharmaceuticals?
In 2022, Ripcord Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.88 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 1.88 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Mar 2019 | Others | ₹1.88 Cr | Open |
How Many Employees Work at Ripcord Pharmaceuticals?
Unlock and access historical data on people associated with Ripcord Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ripcord Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ripcord Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
